The firm is a collaborative drug development company with a strategic investment arm, relying on functional outsourcing to develop novel medications. The firm uses its expertise in over 110 drug development campaigns to identify exceptional companies in which to invest. The firm is interested in seed-stage therapeutics companies, frequently investing in companies recently spun out of academia, with some proof-of-concept data that are looking to hit milestones needed for a Series A raise. The firm is looking to invest in smaller rounds, with tranches of about $200-300K per year for each portfolio company. The firm will invest in companies based in North America, Europe and Israel.
The firm is interested only in companies developing small molecules or biologics. The firm will invest in companies developing new molecules, but will also consider companies developing therapeutics in the 505(b)(2) pathway. The firm is fairly agnostic to indication, with a slight preference for infectious diseases, with the exception of COVID.
The firm looks to be an active investor, taking a board observer seat, at the minimum, and looking to be involved in the development of the product. Using their expertise, the firm can help companies identify the best partners for any studies they may need to accomplish to advance their product pipeline.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply